Cargando…

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects

BACKGROUND: Excessive neutrophil presence and activation is important in a number of acute and chronic inflammatory diseases. The CXCR2 chemokine receptor is important in controlling the extravasation and activation of neutrophils. Selective antagonism of the CXCR2 receptor is a potential approach t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Bruce E., Mistry, Sunil, Smart, Kevin, Connolly, Paul, Carpenter, Donald C., Cooray, Hiran, Bloomer, Jackie C., Tal-Singer, Ruth, Lazaar, Aili L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4475328/ https://www.ncbi.nlm.nih.gov/pubmed/26092545 http://dx.doi.org/10.1186/s40360-015-0017-x

Ejemplares similares

The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers
por: Miller, Bruce E., et al.
Publicado: (2014)

CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin
por: Keir, Holly R., et al.
Publicado: (2020)

Efficacy and Safety of Danirixin (GSK1325756) Co-administered With Standard-of-Care Antiviral (Oseltamivir): A Phase 2b, Global, Randomized Study of Adults Hospitalized With Influenza
por: Madan, Anuradha, et al.
Publicado: (2019)

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial
por: Lazaar, Aili L., et al.
Publicado: (2020)

The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma
por: Singh, Dave, et al.
Publicado: (2010)

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
por: Simon, Marc A., et al.
Publicado: (2022)

The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects
por: Ziauddeen, Hisham, et al.
Publicado: (2013)

Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Clinical Effect of Danirixin in Adults With Acute, Uncomplicated Influenza
por: Roberts, Grace, et al.
Publicado: (2019)

CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking
por: Pluchino, Nicola, et al.
Publicado: (2020)

CXCR4 antagonists for treatment of breast cancer
por: Cortés, Javier, et al.
Publicado: (2018)

Antagonistic role of GSK3 isoforms in glioma survival
por: Vashishtha, Vidhi, et al.
Publicado: (2018)

Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β(2)-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial
por: Ambery, Claire L., et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

Pharmacodynamics of the Glutamate Receptor Antagonists in the Rat Barrel Cortex
por: Vinokurova, Daria, et al.
Publicado: (2018)

Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma
por: Portnoy, Alison, et al.
Publicado: (2013)

Translation Approach for Dentine Regeneration Using GSK-3 Antagonists
por: Zaugg, L.K., et al.
Publicado: (2020)

Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström’s Macroglobulinemia
por: Kaiser, Lisa Marie, et al.
Publicado: (2021)

CCR5 and CXCR4 antagonist and agonist binding sites
por: Teintze, Martin, et al.
Publicado: (2006)

Molecular basis for the antagonistic activity of an anti-CXCR4 antibody
por: Peng, Li, et al.
Publicado: (2015)

Promotion of natural tooth repair by small molecule GSK3 antagonists
por: Neves, Vitor C. M., et al.
Publicado: (2017)

Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study
por: Cahn, Anthony, et al.
Publicado: (2013)

Fluorescent CXCR4 chemokine receptor antagonists: metal activated binding
por: Khan, Abid, et al.
Publicado: (2007)

CXCR4 antagonists in hematologic malignancies: more than just mobilizers?
por: Jo, Deog-Yeon
Publicado: (2011)

EPI-X4, a novel endogenous antagonist of CXCR4
por: Buske, Christian, et al.
Publicado: (2015)

CXCR4 antagonists suppress small cell lung cancer progression
por: Taromi, Sanaz, et al.
Publicado: (2016)

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers
por: Weisel, Kathleen, et al.
Publicado: (2017)

Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers
por: Yang, Lucy, et al.
Publicado: (2017)

Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists
por: Morimoto, Mamoru, et al.
Publicado: (2016)

Phage-Antibiotic Combination Treatments: Antagonistic Impacts of Antibiotics on the Pharmacodynamics of Phage Therapy?
por: Abedon, Stephen T.
Publicado: (2019)

Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist
por: Parameswaran, Reshmi, et al.
Publicado: (2011)

Exploratory Studies on Development of the Chemokine Receptor CXCR4 Antagonists Toward Downsizing
por: Tamamura, Hirokazu, et al.
Publicado: (2008)

PET imaging of CXCR4 using copper-64 labeled peptide antagonist
por: Jacobson, Orit, et al.
Publicado: (2011)

Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists
por: Mishra, Rama K., et al.
Publicado: (2016)

Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
por: Koenig, Lars M., et al.
Publicado: (2020)

A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment
por: Song, Jen-Shin, et al.
Publicado: (2021)

Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t
por: Ward, Richard J., et al.
Publicado: (2020)

CXCR3 antagonist VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK–779
por: Nedjai, Belinda, et al.
Publicado: (2015)

CCR2 and CXCR4 regulate peripheral blood monocyte pharmacodynamics and link to efficacy in experimental autoimmune encephalomyelitis
por: Wang, Yuanfan, et al.
Publicado: (2009)

GSK3β mediates pancreatic cancer cell invasion in vitro via the CXCR4/MMP-2 Pathway
por: Ying, Xu, et al.
Publicado: (2015)

Control of cell migration in the development of the posterior lateral line: antagonistic interactions between the chemokine receptors CXCR4 and CXCR7/RDC1
por: Dambly-Chaudière, Christine, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_r3k8kadjfa7f079tm736o03jsc